Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 9, Pages e1038011
Publisher
Informa UK Limited
Online
2015-05-28
DOI
10.1080/2162402x.2015.1038011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
- (2014) Francesca Donato et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
- (2013) A. C. Chan et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
- (2013) E M Ocio et al. LEUKEMIA
- Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
- (2012) S. Surget et al. CANCER RESEARCH
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals
- (2011) Rosa Barreira da Silva et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
- (2010) A. K. Hsu et al. BLOOD
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Regulation of human NK-cell cytokine and chemokine production by target cell recognition
- (2009) C. Fauriat et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Immunogenic cancer cell death: a key-lock paradigm
- (2008) Antoine Tesniere et al. CURRENT OPINION IN IMMUNOLOGY
- A method for prolonged imaging of motile lymphocytes
- (2008) Daniel Day et al. IMMUNOLOGY AND CELL BIOLOGY
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma
- (2008) Deok-Hwan Yang et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now